ATE247979T1 - Verwendung von hautpenetrationsförderern und für die zerstörung der oberen hautschichten geeigneten mitteln zur erhöhung der durch adp- ribosylating-exotoxin induzierten immunantwort - Google Patents

Verwendung von hautpenetrationsförderern und für die zerstörung der oberen hautschichten geeigneten mitteln zur erhöhung der durch adp- ribosylating-exotoxin induzierten immunantwort

Info

Publication number
ATE247979T1
ATE247979T1 AT99936034T AT99936034T ATE247979T1 AT E247979 T1 ATE247979 T1 AT E247979T1 AT 99936034 T AT99936034 T AT 99936034T AT 99936034 T AT99936034 T AT 99936034T AT E247979 T1 ATE247979 T1 AT E247979T1
Authority
AT
Austria
Prior art keywords
skin
immune response
adpribosylating
exotoxin
destruction
Prior art date
Application number
AT99936034T
Other languages
German (de)
English (en)
Inventor
Gregory M Glenn
Carl B Alving
Original Assignee
Us Gov Sec Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Sec Army filed Critical Us Gov Sec Army
Application granted granted Critical
Publication of ATE247979T1 publication Critical patent/ATE247979T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT99936034T 1998-02-25 1999-02-25 Verwendung von hautpenetrationsförderern und für die zerstörung der oberen hautschichten geeigneten mitteln zur erhöhung der durch adp- ribosylating-exotoxin induzierten immunantwort ATE247979T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7585698P 1998-02-25 1998-02-25
US7585098P 1998-02-25 1998-02-25
PCT/US1999/004128 WO1999043350A1 (en) 1998-02-25 1999-02-25 Use of skin penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response induced by adp-ribosylating exotoxin

Publications (1)

Publication Number Publication Date
ATE247979T1 true ATE247979T1 (de) 2003-09-15

Family

ID=26757358

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99936034T ATE247979T1 (de) 1998-02-25 1999-02-25 Verwendung von hautpenetrationsförderern und für die zerstörung der oberen hautschichten geeigneten mitteln zur erhöhung der durch adp- ribosylating-exotoxin induzierten immunantwort
AT03007948T ATE365050T1 (de) 1998-02-25 1999-02-25 Verwendung von hautpenetrationsförderern und für die zerstörung der oberen hautschichten geeigneten mitteln zur erhöhung der transkutanen immunantwort

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03007948T ATE365050T1 (de) 1998-02-25 1999-02-25 Verwendung von hautpenetrationsförderern und für die zerstörung der oberen hautschichten geeigneten mitteln zur erhöhung der transkutanen immunantwort

Country Status (9)

Country Link
EP (2) EP1061951B1 (enExample)
JP (2) JP4875799B2 (enExample)
AT (2) ATE247979T1 (enExample)
AU (1) AU3311599A (enExample)
BR (1) BR9908278A (enExample)
CA (1) CA2321596C (enExample)
DE (2) DE69910743T2 (enExample)
ES (1) ES2289200T3 (enExample)
WO (1) WO1999043350A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1486215A3 (en) * 1997-03-21 2006-04-12 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
ATE529130T1 (de) * 1999-04-08 2011-11-15 Intercell Usa Inc Trockenformulierung für transkutane immunisierung
US20030078499A1 (en) 1999-08-12 2003-04-24 Eppstein Jonathan A. Microporation of tissue for delivery of bioactive agents
US6835184B1 (en) 1999-09-24 2004-12-28 Becton, Dickinson And Company Method and device for abrading skin
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
US6595947B1 (en) 2000-05-22 2003-07-22 Becton, Dickinson And Company Topical delivery of vaccines
GB0017999D0 (en) 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
WO2002064162A2 (en) * 2001-02-13 2002-08-22 Government Of The United States, As Represented By The Secretary Of The Army Vaccine for transcutaneous immunization
EP1381381A1 (en) * 2001-03-19 2004-01-21 Gregory M. Glenn Patch for transcutaneous immunization
EP2316482A1 (en) 2001-03-19 2011-05-04 Intercell USA, Inc. Transcutaneous immunostimulation
AU2002339121B2 (en) * 2001-05-23 2007-03-22 Duotol Ab Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof
DE60213976T2 (de) 2001-06-08 2007-04-26 Becton Dickinson And Co. Vorrichtung zur manipulation von nadeln oder polierarray
CA2451816A1 (en) 2001-06-29 2003-01-09 Becton, Dickinson And Company Intradermal delivery of vaccines and gene therapeutic agents via microcannula
DE60236806D1 (de) 2001-08-13 2010-08-05 Univ Rochester Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln
AU2002365077A1 (en) * 2001-09-19 2003-06-30 Massachusetts Institute Of Technology Methods and products related to non-viral transfection
AU2003265226A1 (en) 2002-03-11 2003-12-19 Altea Therapeutics Corporation Transdermal drug delivery device, method and use
US9918665B2 (en) 2002-03-11 2018-03-20 Nitto Denko Corporation Transdermal porator and patch system and method for using same
BR0311443A (pt) 2002-05-06 2005-03-22 Becton Dickinson Co Método e dispositivo para controlar farmacocinética de droga
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
EP1545605B8 (en) * 2002-10-02 2010-05-26 Nordic Vaccine A/S Composition for vaccination
EP1590432A4 (en) 2003-01-15 2008-05-14 Res Inst For Genetic And Human DNA COMPOSITION AND ITS USE
US8016811B2 (en) 2003-10-24 2011-09-13 Altea Therapeutics Corporation Method for transdermal delivery of permeant substances
US20060002960A1 (en) * 2003-12-09 2006-01-05 Paul Zoeteweij GM1 binding deficient exotoxins for use as immunoadjuvants
US8092788B2 (en) * 2004-03-03 2012-01-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
SG160357A1 (en) 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP1928537B1 (en) 2005-09-02 2015-01-21 Intercell USA, Inc. Devices for transcutaneous delivery of vaccines and transdermal delivery of drugs
JP5186678B2 (ja) * 2005-10-13 2013-04-17 財団法人ヒューマンサイエンス振興財団 経皮抗原投与のための抗原キット
JP2009511636A (ja) 2005-10-18 2009-03-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
FR2924349B1 (fr) 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
WO2010013350A1 (ja) 2008-08-01 2010-02-04 Ａｓｐｉｏｎ株式会社 Ｓ／ｏ型経皮免疫剤
DE102011018499A1 (de) 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
WO2014044690A1 (en) 2012-09-18 2014-03-27 Valneva Austria Gmbh Improved vaccines
JP6577795B2 (ja) * 2014-09-03 2019-09-18 日東電工株式会社 ビスホスホネート剤を含む細胞性免疫用ワクチン医薬組成物
KR20220147278A (ko) 2021-04-27 2022-11-03 (주)아모레퍼시픽 리포푸신 축적 억제 또는 리포푸신 제거용 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810499A (en) * 1984-10-01 1989-03-07 Biotek, Inc. Transdermal drug delivery system and method
JPS6468327A (en) * 1987-09-08 1989-03-14 Teisan Seiyaku Kk Warming type insulin-containing plaster
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
JPH0679002A (ja) * 1993-12-14 1994-03-22 Hisamitsu Pharmaceut Co Inc 経皮投与用パッチシステム
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
JPH07304690A (ja) * 1994-05-13 1995-11-21 Advanced Sukin Res Kenkyusho:Kk 角質溶解剤、経皮吸収促進剤及び皮膚外用製剤
JP2701005B2 (ja) * 1994-09-07 1998-01-21 株式会社林原生物化学研究所 減感作剤
JPH0912448A (ja) * 1995-04-28 1997-01-14 Read Chem Kk 薬物放出制御型経皮吸収製剤
WO1996037256A1 (en) * 1995-05-22 1996-11-28 Silicon Microdevices, Inc. Micromechanical patch for enhancing the delivery of compounds through the skin
JPH09124468A (ja) * 1995-10-27 1997-05-13 Nippon Zoki Pharmaceut Co Ltd 薬剤内包外皮用貼付剤
RS50101B (sr) * 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
JPH1025243A (ja) * 1996-07-09 1998-01-27 Showa Denko Kk 鎮痛消炎外用貼付剤
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization

Also Published As

Publication number Publication date
EP2286834A2 (en) 2011-02-23
ATE365050T1 (de) 2007-07-15
EP1061951B1 (en) 2003-08-27
DE69936355D1 (de) 2007-08-02
DE69936355T2 (de) 2008-02-21
EP2286834A3 (en) 2012-01-25
CA2321596A1 (en) 1999-09-02
JP2012041355A (ja) 2012-03-01
JP4875799B2 (ja) 2012-02-15
CA2321596C (en) 2012-05-29
AU3311599A (en) 1999-09-15
BR9908278A (pt) 2002-01-02
EP1061951A1 (en) 2000-12-27
JP2002504522A (ja) 2002-02-12
ES2289200T3 (es) 2008-02-01
DE69910743D1 (de) 2003-10-02
WO1999043350A1 (en) 1999-09-02
DE69910743T2 (de) 2004-07-08

Similar Documents

Publication Publication Date Title
ATE247979T1 (de) Verwendung von hautpenetrationsförderern und für die zerstörung der oberen hautschichten geeigneten mitteln zur erhöhung der durch adp- ribosylating-exotoxin induzierten immunantwort
ATE529130T1 (de) Trockenformulierung für transkutane immunisierung
ATE190224T1 (de) Tensidefreie wasser-in-öl emulsion
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
ATE427762T1 (de) Vorlage zur behandlung von hamorrhoiden
FI923743A0 (fi) Med ultraljud effektiverat foerfarande foer levererande av materialer genom huden.
SE9600406D0 (sv) Novel coompounds
ATE244018T1 (de) Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer
ES2063912T3 (es) Composiciones inmunogenicas frente a peptidos de gastrina.
ATE539794T1 (de) Vorrichtung zur verbesserung von hautabsorption und zur transdermalen mittelfreisetzung
DE69229278D1 (de) Humanisierter b-b10, ein anti-il-2-rezeptor-antikörper
DE60134962D1 (de) Anti-ccr4 antikörper und fragmente davon
ES2092460T1 (es) Composicion donadora de oxido nitrico y procedimiento para el tratamiento de trastornos anales.
DE3779587D1 (de) Verfahren und einrichtung zur bestimmung von schwingungseigenschaften sowie zum betreiben eines piezoelektrischen wandlers.
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
ATE391726T1 (de) Modifiziertes gp100 und dessen verwendung
ATE174959T1 (de) Verfahren zur isolierung und kultivierung von transformierten zellen sowie verwendung dieser zellen zur herstellung individuumsspezifischer antikörper
ATE101648T1 (de) Expression eines tumorspezifischen antigens eines rekombinanten virusvektors sowie dessen anwendung zur versorgenden oder heilenden behandlung des entsprechenden tumors.
ATE484294T1 (de) Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
ATE96675T1 (de) Spezifische sekretions-exkretions-antigene von toxoplasma gondii, deren expressionsprodukte, verfahren zu deren herstellung und deren diagnostische und prophylaktische anwendungen.
NO920331D0 (no) Biologisk preparat samt bruk derav
DE69536065D1 (de) Hydrophile Signal-Oligopeptide und Verfahren der therapeutischen Anwendung
IT8967669A0 (it) Macchina per cucire pelle o simila ri avente mezzi di controllo dell ago piatto e metodo per cucire me diante tale macchina
ITMI991605A0 (it) Follatore per il trattamento di cuoio pelli e simili
TR27329A (tr) Yeni metazoan parazit antigenler, bunlari kodlayan nükleik asidler.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties